Trial · NCT00419770

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

NCT00419770, Phase 2, Completed, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; results first posted 2011-10-06

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study. Trials, record NCT00419770. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00419770

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
NCT number: NCT00419770
Status: Completed
Phases: Phase 2
Enrollment: 20 participants, actual
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Conditions: Mucormycosis
Interventions: deferasirox, Placebo, Liposomal amphotericin B
First posted: 2007-01-09
Last updated: 2023-10-16
Results first posted: 2011-10-06

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Safety and Tolerability of Adjunctive Deferasirox Therapy in Patients Being Treated With LAmB for Mucormycosis	14 days
Primary	Global Response Rate (Composite of Clinical and Radiographic Response) at End of Study Drug Administration, as Determined by a Blinded Adjudication Committee	14 days
Primary	Total Adverse Events	30 Days After End of Therapy
Secondary	Deferasirox Pharmacokinetic and Pharmacodynamic Parameters	7 days
Secondary	Survival, Radiographic Improvement, Clinical Response, Time to Survival, Deferasirox vs. Free Iron Level Correlation	Up to 90 days

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Safety and Tolerability of Adjunctive Deferasirox Therapy in Patients Being Treated With LAmB for Mucormycosis	14 days
PRIMARY	Global Response Rate (Composite of Clinical and Radiographic Response) at End of Study Drug Administration, as Determined by a Blinded Adjudication Committee	14 days
SECONDARY	Deferasirox Pharmacokinetic and Pharmacodynamic Parameters	7 days
SECONDARY	Survival, Radiographic Improvement, Clinical Response, Time to Survival, Deferasirox vs. Free Iron Level Correlation	Up to 90 days
PRIMARY	Total Adverse Events	30 Days After End of Therapy	Events	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Total Adverse Events	Deferasirox		16		Events
Total Adverse Events	Placebo		16		Events

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Deferasirox	11
Overall Study	STARTED	Placebo	9
Overall Study	COMPLETED	Deferasirox	6
Overall Study	COMPLETED	Placebo	8
Overall Study	NOT COMPLETED	Deferasirox	5
Overall Study	NOT COMPLETED	Placebo	1

Source ClinicalTrials.gov

Adverse events46

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Thrombocytopenia	Blood and lymphatic system disorders	Deferasirox	0	11	0
other	Thrombocytopenia	Blood and lymphatic system disorders	Placebo	1	9	1
other	Exophthalmos	Blood and lymphatic system disorders	Deferasirox	0	11	0
other	Exophthalmos	Blood and lymphatic system disorders	Placebo	1	9	1
other	Blurry vision	Eye disorders	Deferasirox	0	11	0
other	Blurry vision	Eye disorders	Placebo	1	9	1
other	Diarrhea	Gastrointestinal disorders	Deferasirox	1	11	1
other	Diarrhea	Gastrointestinal disorders	Placebo	1	9	1
other	Vomiting	Gastrointestinal disorders	Deferasirox	0	11	0
other	Vomiting	Gastrointestinal disorders	Placebo	1	9	1

1 to 10 of 46Source ClinicalTrials.gov

See all 46 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Deferasirox
Total, all-cause mortality	Placebo
Total, other adverse events	Deferasirox	8	11
Total, other adverse events	Placebo	7	9
Total, serious adverse events	Deferasirox	8	11
Total, serious adverse events	Placebo	4	9

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
8196268	BACKGROUND	PubMed
16020690	BACKGROUND	PubMed
16928702	BACKGROUND	PubMed
17000743	BACKGROUND	PubMed
21937481	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Deferasirox vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00419770

GET https://conductscience.org/api/trials/v1/NCT00419770/events?page=2

API reference For AI assistants